Top-Rated StocksTop-RatedNASDAQ:SLNO Soleno Therapeutics (SLNO) Stock Price, News & Analysis $68.55 +1.07 (+1.58%) As of 03:39 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Soleno Therapeutics Stock (NASDAQ:SLNO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Soleno Therapeutics alerts:Sign Up Key Stats Today's Range$64.00▼$69.9750-Day Range$43.68▼$73.6752-Week Range$36.61▼$74.00Volume1.09 million shsAverage Volume674,272 shsMarket Capitalization$3.14 billionP/E RatioN/ADividend YieldN/APrice Target$99.63Consensus RatingBuy Company OverviewSoleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.Read More… Remove Ads Soleno Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks90th Percentile Overall ScoreSLNO MarketRank™: Soleno Therapeutics scored higher than 90% of companies evaluated by MarketBeat, and ranked 77th out of 901 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingSoleno Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.22, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSoleno Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Soleno Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Soleno Therapeutics are expected to grow in the coming year, from ($3.72) to ($2.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Soleno Therapeutics is -20.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Soleno Therapeutics is -20.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSoleno Therapeutics has a P/B Ratio of 12.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Soleno Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.91% of the float of Soleno Therapeutics has been sold short.Short Interest Ratio / Days to CoverSoleno Therapeutics has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Soleno Therapeutics has recently increased by 3.74%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSoleno Therapeutics does not currently pay a dividend.Dividend GrowthSoleno Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.55 Percentage of Shares Shorted14.91% of the float of Soleno Therapeutics has been sold short.Short Interest Ratio / Days to CoverSoleno Therapeutics has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Soleno Therapeutics has recently increased by 3.74%, indicating that investor sentiment is decreasing. News and Social Media3.0 / 5News Sentiment0.33 News SentimentSoleno Therapeutics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 36 news articles for Soleno Therapeutics this week, compared to 5 articles on an average week.Search Interest11 people have searched for SLNO on MarketBeat in the last 30 days. This is an increase of 450% compared to the previous 30 days.MarketBeat Follows10 people have added Soleno Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 900% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Soleno Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $64,058,781.00 in company stock.Percentage Held by Insiders12.30% of the stock of Soleno Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.42% of the stock of Soleno Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Soleno Therapeutics' insider trading history. Receive SLNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SLNO Stock News HeadlinesSoleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Sells $265,156.02 in StockApril 3, 2025 | insidertrades.comInsider Selling: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Director Sells $424,792.35 in StockApril 1, 2025 | insidertrades.comThinking of buying Nvidia? Read this firstI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. April 7, 2025 | Porter & Company (Ad)HC Wainwright Issues Optimistic Estimate for SLNO EarningsApril 4 at 1:21 AM | americanbankingnews.comSoleno Therapeutics (NASDAQ:SLNO) Stock Price Down 6.7% on Insider SellingApril 3, 2025 | americanbankingnews.comWinners and wishers: 8 potential Bay Area drug approvals coming this yearApril 2, 2025 | bizjournals.comSoleno Therapeutics (NASDAQ:SLNO) Stock Price Expected to Rise, HC Wainwright Analyst SaysApril 2, 2025 | americanbankingnews.comSoleno Therapeutics price target raised to $100 from $70 at H.C. WainwrightApril 1, 2025 | markets.businessinsider.comSee More Headlines SLNO Stock Analysis - Frequently Asked Questions How have SLNO shares performed this year? Soleno Therapeutics' stock was trading at $44.95 at the beginning of 2025. Since then, SLNO stock has increased by 49.0% and is now trading at $66.9750. View the best growth stocks for 2025 here. How were Soleno Therapeutics' earnings last quarter? Soleno Therapeutics, Inc. (NASDAQ:SLNO) issued its earnings results on Wednesday, March, 5th. The company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($0.86) by $0.41. When did Soleno Therapeutics' stock split? Shares of Soleno Therapeutics reverse split on Friday, August 26th 2022. The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Soleno Therapeutics? Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Soleno Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Soleno Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), e.l.f. Beauty (ELF), Disc Medicine (IRON), Arista Networks (ANET) and Adobe (ADBE). Company Calendar Last Earnings3/05/2025Today4/07/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryMedical Equipment Current SymbolNASDAQ:SLNO CIK1484565 Webwww.soleno.life Phone(650) 213-8444Fax650-213-8383Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$99.63 High Stock Price Target$123.00 Low Stock Price Target$73.00 Potential Upside/Downside+47.6%Consensus RatingBuy Rating Score (0-4)3.22 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($4.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,990,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-61.99% Return on Assets-55.21% Debt Debt-to-Equity RatioN/A Current Ratio17.26 Quick Ratio17.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.16 per share Price / Book13.08Miscellaneous Outstanding Shares45,857,000Free Float37,814,000Market Cap$3.09 billion OptionableOptionable Beta-2.29 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:SLNO) was last updated on 4/7/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThinking of buying Nvidia? Read this firstI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soleno Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.